Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease. (September 2020)

• Record Type: Journal Article
• Authors: Wardlaw, Joanna; Bath, Philip M W; Doubal, Fergus; Heye, Anna; Sprigg, Nikola; Woodhouse, Lisa J; Blair, Gordon; Appleton, Jason; Cvoro, Vera; England, Timothy; Hassan, Ahamad; John Werring, David; Montgomery, Alan
• Is Part Of: European stroke journal. Volume 5:Number 3(2020)
• Page Start: 297
• Page End: 308
• Publication Date: 2020-09
• Subjects: Lacunar stroke -- small vessel disease -- cilostazol -- isosorbide mononitrate -- randomised clinical trial; Cerebrovascular disease -- Periodicals; 616.8005
• DOI: 10.1177/2396987320920110
• Languages: English
• ISSNs: 2396-9873

Abstract

Background: Small vessel disease causes a quarter of ischaemic strokes (lacunar subtype), up to 45% of dementia either as vascular or mixed types, cognitive impairment and physical frailty. However, there is no specific treatment to prevent progression of small vessel disease. Aim: We designed the LACunar Intervention Trial-2 (LACI-2) to test feasibility of a large trial testing cilostazol and/or isosorbide mononitrate (ISMN) by demonstrating adequate participant recruitment and retention in follow-up, drug tolerability, safety and confirm outcome event rates required to power a phase 3 trial. Methods and design: LACI-2 is an investigator-initiated, prospective randomised open label blinded endpoint (PROBE) trial aiming to recruit 400 patients with prior lacunar syndrome due to a small subcortical infarct. We randomise participants to cilostazol v no cilostazol and ISMN or no ISMN, minimising on key prognostic factors. All patients receive guideline-based best medical therapy. Patients commence trial drug at low dose, increment to full dose over 2–4 weeks, continuing on full dose for a year. We follow-up participants to one year for symptoms, tablet compliance, safety, recurrent vascular events, cognition and functional outcomes, Trails B and brain MRI. LACI-2 is registered ISRCTN 14911850, EudraCT 2016–002277-35. Trial outcome: Primary outcome is feasibility of recruitment and compliance; secondary outcomes include safety (cerebral or systemic bleeding, falls, death), efficacy (recurrent cerebral and cardiac vascular events, cognition on TICS, Trails B) and tolerability. Summary: LACI-2 will determine feasibility, tolerability and provide outcome rates to power a large phase 3 trial to prevent progression of cerebral small vessel disease.